---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-012530"
form_type: "8-K"
ticker: "ZBH"
cik: "0001136869"
company_name: "ZIMMER BIOMET HOLDINGS, INC."
filed_at: "2024-02-08T23:59:59+00:00"
generated_at: "2026-06-06T05:21:18.499318+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zimmer Biomet Q4 2023 net sales $1.94B (+6.3%), adj EPS $2.20; guides FY24 adj EPS $8.00-$8.15

## Summary
- Q4 net sales $1.94B (+6.3% reported, +6.1% CC); diluted EPS $2.01, adjusted $2.20.
- Full-year 2023 net sales $7.39B (+6.5% reported, +7.5% CC); adjusted EPS $7.55.
- FY 2024 guidance: constant currency revenue growth 5.0%-6.0%; adjusted diluted EPS $8.00-$8.15.
- FDA closed out Warning Letter for Warsaw North Campus; global restructuring targeting ~$200M run-rate savings by 2025.
- Completed $500M share buyback in Jan 2024; appointed Louis Shapiro to board.

## SEC filing metadata
- accession: 0000950170-24-012530
- form_type: 8-K
- ticker: ZBH
- cik: 0001136869
- company_name: ZIMMER BIOMET HOLDINGS, INC.
- filed_at: 2024-02-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1136869/000095017024012530/0000950170-24-012530-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1136869/000095017024012530/zbh-20240208.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-012530
- JSON: https://secwatch.observer/filing/0000950170-24-012530.json
- Plain text: https://secwatch.observer/filing/0000950170-24-012530.txt

## Key facts
- Earnings Releases
  ZIMMER BIOMET HOLDINGS, INC. reported year ending December 31, 2024 results: revenue 2024 Reported Revenue Change 4.5% - 5.5%, EPS Adjusted Diluted EPS $8.00 - $8.15. Guidance reaffirmed.
  - Period: year ending December 31, 2024
  - Revenue: 2024 Reported Revenue Change 4.5% - 5.5%
  - EPS: Adjusted Diluted EPS $8.00 - $8.15
  - Guidance: reaffirmed
  - Result: guidance update
  source text: The Company is providing the following full-year 2024 financial guidance: Projected Year Ending December 31, 2024 2024 Reported Revenue Change 4.5% - 5.5%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1136869/000095017024012530/0000950170-24-012530-index.htm
- Earnings Releases
  ZIMMER BIOMET HOLDINGS, INC. reported quarter and year ended December 31, 2023 results: revenue Fourth quarter net sales of $1.940 billion; Full-year net sales of $7.394 billion, net income Net earnings for the fourth quarter were $419.2 million; For the full year, net earnings were $1.024 billion, EPS Diluted earnings per share were $2.01 for the fourth quarter; Full-year diluted earnings per share were $4.88.
  - Period: quarter and year ended December 31, 2023
  - Revenue: Fourth quarter net sales of $1.940 billion; Full-year net sales of $7.394 billion
  - Net income: Net earnings for the fourth quarter were $419.2 million; For the full year, net earnings were $1.024 billion
  - EPS: Diluted earnings per share were $2.01 for the fourth quarter; Full-year diluted earnings per share were $4.88
  - Result: reported results
  source text: heather.zoumaslubeski@zimmerbiomet.com zach.weiner@zimmerbiomet.com Zimmer Biomet Announces Fourth Quarter and Full-Year 2023 Financial Results • Fourth quarter net sales of $1.940 billion increased 6.3% and 6.1% on a constant currency 1 basis • Fourth quarter diluted earnings per share were $2.01; adjusted 1 diluted earnings per share were $2.20 • Full-year net
  evidence_url: https://www.sec.gov/Archives/edgar/data/1136869/000095017024012530/0000950170-24-012530-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.